Should I buy or sell Augmedix stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Augmedix in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" AUGX shares. View AUGX analyst ratings or view top-rated stocks .

What is Augmedix's stock price target for 2024?

3 brokerages have issued 12 month price objectives for Augmedix's shares. Their AUGX share price targets range from $6.00 to $8.00. On average, they expect the company's share price to reach $6.83 in the next year. This suggests a possible upside of 128.5% from the stock's current price. View analysts price targets for AUGX or view top-rated stocks among Wall Street analysts .

How have AUGX shares performed in 2024?

Augmedix's stock was trading at $5.85 on January 1st, 2024. Since then, AUGX shares have decreased by 48.9% and is now trading at $2.99. View the best growth stocks for 2024 here .

How were Augmedix's earnings last quarter?

Augmedix, Inc. (OTCMKTS:AUGX) posted its quarterly earnings results on Monday, March, 18th. The company reported ($0.09) earnings per share (EPS) for the quarter. The business had revenue of $12.68 million for the quarter, compared to the consensus estimate of $12.30 million. Augmedix had a negative net margin of 57.70% and a negative trailing twelve-month return on equity of 980.09%.

How do I buy shares of Augmedix?

Shares of AUGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

OTCMKTS:AUGX

Augmedix (AUGX) Stock Price, News & Analysis

→ Tiny Biotech Stock Wins $75 Billion Patent (From Behind the Markets) (Ad)

Free AUGX Stock Alerts

$2.99

-0.02 (-0.66%)

(As of 04/19/2024 ET)

Compare

Today's Range: $2.82
▼
$3.12
50-Day Range: $3.01
▼
$4.70
52-Week Range: $1.75
▼
$6.25

Volume: 289,855 shs
Average Volume: 375,679 shs
Market Capitalization: $145.73 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $6.83

Stock Analysis Analyst Forecasts Chart Earnings Financials Headlines Insider Trades Ownership SEC Filings

Get Augmedix alerts:

Augmedix MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 128.5% Upside
$6.83 Price Target
Short Interest: N/A
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.22
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.48) to ($0.36) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.12 out of 5 stars

3.5

Analyst's Opinion

Consensus Rating
Augmedix has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Augmedix has received no research coverage in the past 90 days.

N/A

Short Interest

Short Interest
There is no current short interest data available for AUGX.

0.0

Dividend Strength

Dividend Yield
Augmedix does not currently pay a dividend.
Dividend Growth
Augmedix does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for AUGX.

2.3

News and Social Media Coverage

News Sentiment
Augmedix has a news sentiment score of 0.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Augmedix this week, compared to 1 article on an average week.
Search Interest
Only 3 people have searched for AUGX on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days.
MarketBeat Follows
1 people have added Augmedix to their MarketBeat watchlist in the last 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Augmedix insiders have not sold or bought any company stock.
Percentage Held by Insiders
10.97% of the stock of Augmedix is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
87.11% of the stock of Augmedix is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Augmedix are expected to grow in the coming year, from ($0.48) to ($0.36) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Augmedix is -5.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Augmedix is -5.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Augmedix has a P/B Ratio of 29.90. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Behind the Markets

Tiny Biotech Stock Wins $75 Billion Patent

A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.

Find out more here >>>

About Augmedix Stock (OTCMKTS:AUGX)

Augmedix, Inc. provides remote medical documentation solutions and live clinical support services in the United States. Its platform offers Augmedix Live that provides synchronous medical note documentation and point of care support; Augmedix Go Assist that offers asynchronous medical documentation based upon previously recorded visits; Augmedix Prep that provides patient demographics, past medical history, medication changes and other points from the patient's health record; and Augmedix Go, an autonomous, ambient AI mobile software application that offers fully automated medical documentation based upon recorded visits. The company enables clinicians to access its applications through mobile devices, such as smartphones. It serves health systems and specialty groups. The company was founded in 2013 and is headquartered in San Francisco, California.

AUGX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

AUGX Stock News Headlines

April 18, 2024 | americanbankingnews.com

Head to Head Comparison: Augmedix (OTCMKTS:AUGX) versus Mobile-health Network Solutions (NASDAQ:MNDR)

April 14, 2024 | americanbankingnews.com

Augmedix (OTCMKTS:AUGX) versus Zhongchao (NASDAQ:ZCMD) Head-To-Head Survey

April 19, 2024 | Behind the Markets (Ad)

Tiny Biotech Stock Wins $75 Billion Patent

April 10, 2024 | finance.yahoo.com

Augmedix Inc (AUGX) Chief Strategy Officer Ian Shakil Sells 89,167 Shares

April 4, 2024 | uk.finance.yahoo.com

Augmedix Inc (AUGX) Chief Strategy Officer Ian Shakil Sells 97,441 Shares

April 4, 2024 | finanznachrichten.de

Augmedix Inc: Augmedix and SADA Forge Partnership to Scale Ambient Documentation and Structured Data Products to Health Systems Nationwide

March 19, 2024 | finanznachrichten.de

Augmedix Inc: Augmedix Delivers 45% Revenue Growth and Expanded Gross Margins for Fourth Quarter of 2023

March 19, 2024 | markets.businessinsider.com

Benchmark Co. Keeps Their Buy Rating on Augmedix (AUGX)

April 19, 2024 | Behind the Markets (Ad)

Tiny Biotech Stock Wins $75 Billion Patent

March 18, 2024 | investorplace.com

AUGX Stock Earnings: Augmedix Beats EPS, Beats Revenue for Q4 2023

March 18, 2024 | finance.yahoo.com

Augmedix Inc (AUGX) Reports Strong Revenue Growth and Margin Expansion in Q4 and Full Year 2023

March 16, 2024 | finance.yahoo.com

AUGX Mar 2024 7.500 call

March 16, 2024 | finance.yahoo.com

AUGX Apr 2024 5.000 call

March 12, 2024 | finanznachrichten.de

Augmedix Inc: Augmedix Announces New Positive Data and Enhancements to Its Ambient AI Product, Augmedix Go

February 25, 2024 | edition.cnn.com

Augmedix Inc

February 15, 2024 | bizjournals.com

Daily Digest: Cisco releases layoff total; A's in Coliseum extension talks

February 13, 2024 | finance.yahoo.com

Augmedix Names Tomer Levy as New Senior Vice President of Engineering

January 30, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Augmedix Amid Funding Success and Strong Growth Prospects

January 16, 2024 | finance.yahoo.com

Augmedix Announces Participation in Maxim Group Virtual Healthcare IT Investor Conference

January 7, 2024 | benzinga.com

Augmedix Stock (NASDAQ:AUGX) Dividends: History, Yield and Dates

January 6, 2024 | msn.com

Augmedix says Q4 revenue is expected to be about $12.5M

December 13, 2023 | finance.yahoo.com

Augmedix Partners with Google Cloud to Bring Medically-Tuned AI Technology to Ambient Documentation

December 9, 2023 | finance.yahoo.com

Augmedix, Inc. (NASDAQ:AUGX) has caught the attention of hedge funds investors who hold a sizeable 40% stake

November 27, 2023 | msn.com

Augmedix (AUGX) Price Target Increased by 7.60% to 7.82

November 24, 2023 | uk.finance.yahoo.com

Augmedix, Inc. (AUGX)

November 16, 2023 | investorplace.com

Why Is Augmedix (AUGX) Stock Down 27% Today?

November 15, 2023 | finance.yahoo.com

Augmedix Announces Proposed Public Offering of 5,500,000 Shares of Common Stock

See More Headlines

Receive AUGX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Augmedix and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/18/2024
Today: 4/19/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Sector: Medical
Industry: Health Information Services
Sub-Industry: N/A
Current Symbol: OTCMKTS:AUGX
CUSIP: N/A
CIK: 1769804
Web: www.augmedix.com
Phone: 888-669-4885
Fax: N/A
Employees: 1,040
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $6.83
High Stock Price Target: $8.00
Low Stock Price Target: $6.00
Potential Upside/Downside: +127.0%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.45)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-24,450,000.00
Net Margins: -57.70%
Pretax Margin: -57.23%
Return on Equity: -980.09%
Return on Assets: -57.85%

Debt

Debt-to-Equity Ratio: 3.74
Current Ratio: 1.70
Quick Ratio: 1.70

Sales & Book Value

Annual Sales: $44.86 million
Price / Sales: 3.27
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.10 per share
Price / Book: 30.10

Miscellaneous

Outstanding Shares: 48,740,000
Free Float: 36,316,000
Market Cap: $146.71 million
Optionable: Not Optionable
Beta: -0.16

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

Mr. Emmanuel Krakaris (Age 65)
President, CEO, Secretary & Director
Comp: $734.33k
Mr. Ian Shakil (Age 39)
Founder, Chief Strategy Officer & Director
Ms. Sandra Breber (Age 66)
Chief Operating Officer
Comp: $446.05k
Mr. Saurav Chatterjee Ph.D. (Age 52)
Chief Technology Officer
Comp: $438.05k
Mr. Paul Louis Ginocchio (Age 54)
Chief Financial Officer
Todd Holvick
Head of Legal & Compliance
Lia Wallick
Head of People
Dr. Davin Lundquist M.D.
Chief Medical Officer
Mr. Jonathan Hawkins (Age 54)
Chief Revenue Officer
Comp: $417.71k
Mr. Tomer Levy
Senior Vice President of Engineering

Key Competitors

View All Competitors

Insiders

Margie L Traylor
Bought 26,530 shares on 6/14/2023
Total: $119,650.30 ($4.51/share)

View All Insider Transactions

AUGX Stock Analysis - Frequently Asked Questions

Should I buy or sell Augmedix stock right now?: 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Augmedix in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" AUGX shares.
View AUGX analyst ratings or view top-rated stocks.
What is Augmedix's stock price target for 2024?: 3 brokerages have issued 12 month price objectives for Augmedix's shares. Their AUGX share price targets range from $6.00 to $8.00. On average, they expect the company's share price to reach $6.83 in the next year. This suggests a possible upside of 128.5% from the stock's current price.
View analysts price targets for AUGX or view top-rated stocks among Wall Street analysts.
How have AUGX shares performed in 2024?: Augmedix's stock was trading at $5.85 on January 1st, 2024. Since then, AUGX shares have decreased by 48.9% and is now trading at $2.99.
View the best growth stocks for 2024 here.

How were Augmedix's earnings last quarter?: Augmedix, Inc. (OTCMKTS:AUGX) posted its quarterly earnings results on Monday, March, 18th. The company reported ($0.09) earnings per share (EPS) for the quarter. The business had revenue of $12.68 million for the quarter, compared to the consensus estimate of $12.30 million. Augmedix had a negative net margin of 57.70% and a negative trailing twelve-month return on equity of 980.09%.
How do I buy shares of Augmedix?: Shares of AUGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:AUGX) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Augmedix (AUGX) Stock Price, News & Analysis

Augmedix MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Short Interest

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Augmedix Stock (OTCMKTS:AUGX)

AUGX Stock Price History

AUGX Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders

AUGX Stock Analysis - Frequently Asked Questions

Overall MarketRank^™